Therapeutic strategies to inhibit MYC.

MYC is a master regulator of stem cell state, embryogenesis, tissue homeostasis, and aging. As in health, in disease MYC figures prominently. Decades of biological research have identified a central role for MYC in the pathophysiology of cancer, inflammation, and heart disease. The centrality of MYC to such a vast breadth of disease biology has attracted significant attention to the historic challenge of developing inhibitors of MYC. This review will discuss therapeutic strategies toward the development of inhibitors of MYC-dependent transcriptional signaling, efforts to modulate MYC stability, and the elusive goal of developing potent, direct-acting inhibitors of MYC.

[1]  S. Robinson,et al.  Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma. , 2016, Cancer cell.

[2]  S. R. Hann.  MYC cofactors: molecular switches controlling diverse biological outcomes. , 2014, Cold Spring Harbor perspectives in medicine.

[3]  D. Felsher,et al.  MYC activation is a hallmark of cancer initiation and maintenance. , 2014, Cold Spring Harbor perspectives in medicine.

[4]  Jason J Burbank,et al.  Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. , 2014, The Journal of clinical investigation.

[5]  L. Staudt,et al.  Oncogenic mechanisms in Burkitt lymphoma. , 2014, Cold Spring Harbor perspectives in medicine.

[6]  Bruno Amati,et al.  Genome recognition by MYC. , 2014, Cold Spring Harbor perspectives in medicine.

[7]  R. Eisenman,et al.  An overview of MYC and its interactome. , 2014, Cold Spring Harbor perspectives in medicine.

[8]  R. Sears,et al.  MYC degradation. , 2014, Cold Spring Harbor perspectives in medicine.

[9]  R. Young,et al.  MYC and transcription elongation. , 2014, Cold Spring Harbor perspectives in medicine.

[10]  Nir London,et al.  Druggable protein-protein interactions--from hot spots to hot segments. , 2013, Current opinion in chemical biology.

[11]  Charles Y. Lin,et al.  Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. , 2013, Cancer cell.

[12]  R. Pieters,et al.  NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern , 2013, Leukemia.

[13]  M. Roussel,et al.  Role of MYC in Medulloblastoma. , 2013, Cold Spring Harbor perspectives in medicine.

[14]  Soyoung Lee,et al.  Synthetic lethal metabolic targeting of cellular senescence in cancer therapy , 2013, Nature.

[15]  Travis J Cohoon,et al.  Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.

[16]  P. Hurlin.  Control of vertebrate development by MYC. , 2013, Cold Spring Harbor perspectives in medicine.

[17]  Giovanni Roti,et al.  Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. , 2013, Chemistry & biology.

[18]  D C Swinney,et al.  Phenotypic vs. Target‐Based Drug Discovery for First‐in‐Class Medicines , 2013, Clinical pharmacology and therapeutics.

[19]  G. Evan,et al.  Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. , 2013, Genes & development.

[20]  E. Prochownik,et al.  Pharmacophore identification of c-Myc inhibitor 10074-G5. , 2013, Bioorganic & medicinal chemistry letters.

[21]  D. Levens.  Cellular MYCro economics: Balancing MYC function with MYC expression. , 2013, Cold Spring Harbor perspectives in medicine.

[22]  Giovanna Zinzalla,et al.  Small-molecule inhibition of c-MYC:MAX leucine zipper formation is revealed by ion mobility mass spectrometry. , 2012, Journal of the American Chemical Society.

[23]  J. Bradner,et al.  Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML) , 2012, Oncotarget.

[24]  Christopher J. Ott,et al.  BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. , 2012, Blood.

[25]  Aaron N. Chang,et al.  Functional genomics identifies therapeutic targets for MYC-driven cancer , 2012, Proceedings of the National Academy of Sciences.

[26]  A. Gingras,et al.  Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family , 2012, Cell.

[27]  Julie D. Forman-Kay,et al.  Transient structure and dynamics in the disordered c-Myc transactivation domain affect Bin1 binding , 2012, Nucleic acids research.

[28]  R. Prinjha,et al.  Place your BETs: the therapeutic potential of bromodomains. , 2012, Trends in pharmacological sciences.

[29]  Ji Luo,et al.  A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis , 2012, Science.

[30]  D. Green,et al.  The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. , 2011, Immunity.

[31]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[32]  P. Sandy,et al.  Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.

[33]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[34]  M. Rask-Andersen,et al.  Trends in the exploitation of novel drug targets , 2011, Nature Reviews Drug Discovery.

[35]  Danzhou Yang,et al.  c-MYC promoter G-quadruplex formed at the 5′-end of NHE III1 element: insights into biological relevance and parallel-stranded G-quadruplex stability , 2011, Nucleic acids research.

[36]  G. Evan,et al.  The Action Mechanism of the Myc Inhibitor Termed Omomyc May Give Clues on How to Target Myc for Cancer Therapy , 2011, PloS one.

[37]  Yonghong Xiao,et al.  Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. , 2011, Cancer cell.

[38]  Adrian Whitty,et al.  Growing PAINS in academic drug discovery. , 2011, Future medicinal chemistry.

[39]  Jun O. Liu,et al.  XPB, a subunit of TFIIH, is a target of the natural product triptolide. , 2011, Nature chemical biology.

[40]  E. Prochownik,et al.  In Vitro Cytotoxicity and In Vivo Efficacy, Pharmacokinetics, and Metabolism of 10074-G5, a Novel Small-Molecule Inhibitor of c-Myc/Max Dimerization , 2010, Journal of Pharmacology and Experimental Therapeutics.

[41]  R. Eisenman,et al.  Essential Functions of the Histone Demethylase Lid , 2010, PLoS genetics.

[42]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[43]  S. Metallo,et al.  Intrinsically disordered proteins are potential drug targets. , 2010, Current opinion in chemical biology.

[44]  Hong Liu,et al.  Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase , 2010, Proceedings of the National Academy of Sciences.

[45]  Chul-hak Yang,et al.  Small-molecule inhibitors of c-Myc transcriptional factor suppress proliferation and induce apoptosis of promyelocytic leukemia cell via cell cycle arrest. , 2010, Molecular bioSystems.

[46]  Ruben Abagyan,et al.  Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. , 2010, Chemistry & biology.

[47]  Yibin Wang,et al.  Myc controls transcriptional regulation of cardiac metabolism and mitochondrial biogenesis in response to pathological stress in mice. , 2010, The Journal of clinical investigation.

[48]  Christopher B. Burge,et al.  c-Myc Regulates Transcriptional Pause Release , 2010, Cell.

[49]  Stephen V Frye,et al.  The art of the chemical probe. , 2010, Nature chemical biology.

[50]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[51]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[52]  Michael D. Cole,et al.  Upregulation of c-MYC in cis through a Large Chromatin Loop Linked to a Cancer Risk-Associated Single-Nucleotide Polymorphism in Colorectal Cancer Cells , 2010, Molecular and Cellular Biology.

[53]  Raymond E. Moellering,et al.  Direct inhibition of the NOTCH transcription factor complex , 2010, Nature.

[54]  Landon R. Whitby,et al.  Small molecule inhibitors of Myc/Max dimerization and Myc-induced cell transformation. , 2009, Bioorganic & medicinal chemistry letters.

[55]  Salvatore Oliviero,et al.  Histone Crosstalk between H3S10ph and H4K16ac Generates a Histone Code that Mediates Transcription Elongation , 2009, Cell.

[56]  Ariele Viacava Follis,et al.  Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. , 2009, Journal of the American Chemical Society.

[57]  Dinshaw J. Patel,et al.  Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger , 2009, Nature.

[58]  M. Babu,et al.  The rules of disorder or why disorder rules. , 2009, Progress in biophysics and molecular biology.

[59]  E. Prochownik,et al.  Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc–Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice , 2009, Cancer Chemotherapy and Pharmacology.

[60]  L. Penn,et al.  Reflecting on 25 years with MYC , 2008, Nature Reviews Cancer.

[61]  S. Teichmann,et al.  Tight Regulation of Unstructured Proteins: From Transcript Synthesis to Protein Degradation , 2008, Science.

[62]  Ariele Viacava Follis,et al.  Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. , 2008, Chemistry & biology.

[63]  Tony Fletcher,et al.  Sequence variant on 8q24 confers susceptibility to urinary bladder cancer , 2008, Nature Genetics.

[64]  R. Eisenman,et al.  Myc's broad reach. , 2008, Genes & development.

[65]  G. Evan,et al.  Modelling Myc inhibition as a cancer therapy , 2008, Nature.

[66]  Kenneth A. Johnson,et al.  Role of Induced Fit in Enzyme Specificity: A Molecular Forward/Reverse Switch* , 2008, Journal of Biological Chemistry.

[67]  T. Berg.  Inhibition of transcription factors with small organic molecules. , 2008, Current opinion in chemical biology.

[68]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[69]  T. Mahmoudi,et al.  Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription , 2007, Proceedings of the National Academy of Sciences.

[70]  S. Mujtaba,et al.  Structure and acetyl-lysine recognition of the bromodomain , 2007, Oncogene.

[71]  S. Oliviero,et al.  PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation , 2007, Nature Cell Biology.

[72]  Lester L. Peters,et al.  Genome-wide association study identifies novel breast cancer susceptibility loci , 2007, Nature.

[73]  A. Tward,et al.  Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC , 2007, Nature Medicine.

[74]  R. Eisenman,et al.  The Function and Regulation of the JARID1 Family of Histone H3 Lysine 4 Demethylases: the Myc Connection , 2007, Cell cycle.

[75]  Bianca Sperl,et al.  Selective Inhibition of c‐Myc/Max Dimerization by a Pyrazolo[1,5‐a]pyrimidine , 2007, ChemMedChem.

[76]  Steven Fletcher,et al.  Protein-protein interaction inhibitors: small molecules from screening techniques. , 2007, Current topics in medicinal chemistry.

[77]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[78]  R. Eisenman,et al.  The Trithorax group protein Lid is a trimethyl histone H3K4 demethylase required for dMyc-induced cell growth. , 2007, Genes & development.

[79]  D. V. Von Hoff,et al.  Drug targeting of the c-MYC promoter to repress gene expression via a G-quadruplex silencer element. , 2006, Seminars in oncology.

[80]  M. Cole,et al.  Mechanism of transcriptional activation by the Myc oncoproteins. , 2006, Seminars in cancer biology.

[81]  Kathryn A. O’Donnell,et al.  The c-Myc target gene network. , 2006, Seminars in cancer biology.

[82]  J. Aster,et al.  c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. , 2006, Genes & development.

[83]  Dirk Eick,et al.  Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules. , 2006, Chemistry & biology.

[84]  Philip R. Gafken,et al.  Myc influences global chromatin structure , 2006, The EMBO journal.

[85]  M. Cole,et al.  A Conserved Myc Protein Domain, MBIV, Regulates DNA Binding, Apoptosis, Transformation, and G2 Arrest , 2006, Molecular and Cellular Biology.

[86]  P. Vogt,et al.  A credit-card library approach for disrupting protein-protein interactions. , 2006, Bioorganic & medicinal chemistry.

[87]  P. Cole,et al.  Synthesis and evaluation of a potent and selective cell-permeable p300 histone acetyltransferase inhibitor. , 2005, Journal of the American Chemical Society.

[88]  Ernest Martinez,et al.  Dual Regulation of c-Myc by p300 via Acetylation-Dependent Control of Myc Protein Turnover and Coactivation of Myc-Induced Transcription , 2005, Molecular and Cellular Biology.

[89]  Andreas Trumpp,et al.  c-Myc Is Required for the Formation of Intestinal Crypts but Dispensable for Homeostasis of the Adult Intestinal Epithelium , 2005, Molecular and Cellular Biology.

[90]  Gordon K Smyth,et al.  Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[91]  S. Lowe,et al.  A conserved element in Myc that negatively regulates its proapoptotic activity , 2005, EMBO reports.

[92]  P. Petrow,et al.  Cooperation of Ras- and c-Myc-dependent pathways in regulating the growth and invasiveness of synovial fibroblasts in rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[93]  G. Evan,et al.  Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia , 2004, Oncogene.

[94]  K. Nakayama,et al.  Phosphorylation‐dependent degradation of c‐Myc is mediated by the F‐box protein Fbw7 , 2004, The EMBO journal.

[95]  B. Clurman,et al.  The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[96]  S. Kim,et al.  Multiple cell-type-specific elements regulate Myc protein stability , 2004, Oncogene.

[97]  Chul-hak Yang,et al.  Determination of binding constant of transcription factor myc-max/max-max and E-box DNA: the effect of inhibitors on the binding. , 2004, Biochimica et biophysica acta.

[98]  Roberto Sanchez,et al.  Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. , 2004, Molecular cell.

[99]  John S Lazo,et al.  Low molecular weight inhibitors of Myc–Max interaction and function , 2003, Oncogene.

[100]  Tom Misteli,et al.  The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[101]  Stephen K. Burley,et al.  X-Ray Structures of Myc-Max and Mad-Max Recognizing DNA Molecular Bases of Regulation by Proto-Oncogenic Transcription Factors , 2003, Cell.

[102]  J. Darnell.  Transcription factors as targets for cancer therapy , 2002, Nature Reviews Cancer.

[103]  D. Bearss,et al.  Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[104]  Kenneth Chu,et al.  Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC , 2002, Science.

[105]  L. Soucek,et al.  Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis. , 2002, Cancer research.

[106]  G. Evan,et al.  Suppression of Myc-Induced Apoptosis in β Cells Exposes Multiple Oncogenic Properties of Myc and Triggers Carcinogenic Progression , 2002, Cell.

[107]  D. Boger,et al.  Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[108]  D. Langley,et al.  Selective interactions of cationic porphyrins with G-quadruplex structures. , 2001, Journal of the American Chemical Society.

[109]  Y Taya,et al.  Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. , 2000, Genes & development.

[110]  J. Williamson.  Induced fit in RNA–protein recognition , 2000, Nature Structural Biology.

[111]  A. Zetterberg,et al.  Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[112]  L. Hurley,et al.  Inhibition of unwinding of G-quadruplex structures by Sgs1 helicase in the presence of N,N'-bis[2-(1-piperidino)ethyl]-3,4,9,10-perylenetetracarboxylic diimide, a G-quadruplex-interactive ligand. , 2000, Biochemistry.

[113]  L. Hurley,et al.  G-quadruplex DNA: a potential target for anti-cancer drug design. , 2000, Trends in pharmacological sciences.

[114]  M. Cole,et al.  The Essential Cofactor TRRAP Recruits the Histone Acetyltransferase hGCN5 to c-Myc , 2000, Molecular and Cellular Biology.

[115]  H. Dyson,et al.  Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. , 1999, Journal of molecular biology.

[116]  D. Felsher,et al.  Reversible tumorigenesis by MYC in hematopoietic lineages. , 1999, Molecular cell.

[117]  E. Prochownik,et al.  MYC oncogenes and human neoplastic disease , 1999, Oncogene.

[118]  L. Hurley,et al.  Accelerated assembly of G-quadruplex structures by a small molecule. , 1999, Biochemistry.

[119]  G. Evan,et al.  Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. , 1999, Molecular cell.

[120]  L. Hurley,et al.  A DNA polymerase stop assay for G-quadruplex-interactive compounds. , 1999, Nucleic acids research.

[121]  M. Helmer-Citterich,et al.  Design and properties of a Myc derivative that efficiently homodimerizes , 1998, Oncogene.

[122]  P. Picci,et al.  C-myc and c-fos in Human Osteosarcoma: Prognostic Value of mRNA and Protein Expression , 1998, Oncology.

[123]  M. Cole,et al.  The Novel ATM-Related Protein TRRAP Is an Essential Cofactor for the c-Myc and E2F Oncoproteins , 1998, Cell.

[124]  M. Ptashne,et al.  Transcriptional activation by recruitment , 1997, Nature.

[125]  P. Carroll,et al.  c-myc copy number gains in bladder cancer detected by fluorescence in situ hybridization. , 1995, The American journal of pathology.

[126]  A. Bradley,et al.  A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. , 1993, Genes & development.

[127]  M. Lohuizen,et al.  Very high frequency of lymphoma induction by a chemical carcinogen in pim-1 transgenic mice , 1989, Nature.

[128]  A. Berns,et al.  Predisposition to lymphomagenesis in pim-1 transgenic mice: Cooperation with c-myc and N-myc in murine leukemia virus-induced tumors , 1989, Cell.

[129]  P. Leder,et al.  Translocations among antibody genes in human cancer. , 1983, Science.

[130]  G. Klein.  Specific chromosomal translocations and the genesis of B-cell-derived tumors in mice and men , 1983, Cell.

[131]  C. Croce,et al.  Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[132]  P. Leder,et al.  Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[133]  J. Bishop,et al.  DNA and RNA from Uninfected Vertebrate Cells Contain Nucleotide Sequences Related to the Putative Transforming Gene of Avian Myelocytomatosis Virus , 1979, Journal of virology.

[134]  P. Vogt,et al.  Avian acute leukemia viruses MC29 and MH2 share specific RNA sequences: evidence for a second class of transforming genes. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[135]  P. Vogt,et al.  Avian oncovirus MH2 is defective in Gag, Pol, and Env. , 1979, Virology.